XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.
Stocks · News reference
XORTX Therapeutics shares are trading higher after the company announced an outline of its anticipated Clinical Trial Application submission to Health Canada for the XRx-026 gout program.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading